CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Non-Small Cell Lung Cancer|Renal Cell Cancer|Colorectal Cancer|Triple Negative Breast Cancer|Cervical Cancer|Ovarian Cancer|Pancreatic Cancer|Endometrial Cancer|Sarcoma|Squamous Cell Carcinoma of the Head and Neck|Bladder Cancer|Metastatic Castration Resistant Prostate Cancer|Non-hodgkin Lymphoma
Interventions: DRUG: CPI-006|DRUG: CPI-006 + ciforadenant|DRUG: CPI-006 + pembrolizumab|DRUG: CPI-006|DRUG: CPI-006 + ciforadenant|DRUG: CPI-006 + pembrolizumab
Sponsor: Corvus Pharmaceuticals, Inc.